Le Lézard
Classified in: Science and technology, Business
Subject: ACC

DelphX Grants Stock Options


TORONTO, July 9, 2019 /CNW/ - DelphX Capital Markets Inc. (TSXV: DELX) ("DelphX") announced that the Board of Directors has approved the grant of 2,700,000 stock options (the "Options") to eligible participants under its stock option plan (the "Plan"). The options vest on September 30, 2019 and are exercisable for common shares of DelphX at an exercise price of $0.12 per common share and have a 2-year maturity, all in accordance with the Plan.

Subsequent to this grant, DelphX has 7,279,000 options outstanding and a further 1,633,988 common shares are reserved for issuance upon the exercise of options that may be granted pursuant to the Plan.

About DelphX: 

DelphX is a technology and financial services company focused on optimizing fixed income markets. Its Cloud-based platform employs distributed ledger technology, actuarial science and reinsurance protocols to enable fixed income dealers to offer new Rule 144A securities that optimally diffuse credit risk. The new DelphX platform will be regulated by the SEC and enable dealers to competitively structure, sell and make markets in:

All CPOs and CRNs will be collateralized by investment grade assets held in custody by an independent custodian and transparently administered within DelphX's immutable distributed ledger. A traditional book-entry record of each security will also be maintained in parallel by an independent issuing and paying agent to provide additional transparency and efficiency.

For more information about DelphX, please visit www.delphx.com.

Forward-Looking Statements

This news release contains certain "forward-looking statements" including, without limitation, statements regarding the launch of the DelphX platform. Such forward-looking statements involve risks and uncertainties, both known and unknown. The results or events depicted in these forward-looking statements may differ materially from actual results or events. In addition to other factors and assumptions which may be identified herein, assumptions have been made regarding and are implicit in, among other things: the state of the capital markets, tax issues associated with doing business internationally, the ability of DelphX to successfully manage the risks inherent in pursuing business opportunities in the financial services and Blockchain industry, and the ability of DelphX to obtain qualified staff, equipment and services in a timely and cost-efficient manner to develop its business. Any forward-looking statement reflects information available to DelphX as of the date of this news release and, except as may be required by applicable securities laws, DelphX disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE DelphX Capital Markets Inc.


These press releases may also interest you

at 18:15
Epiq, a global technology-enabled leader to the legal industry and corporations, announced today Epiq Facilitatortm the premier, reliable, secure application for retrieving information, managing legal analysis, and administering voluntary...

at 18:05
CrowdStrike announced the winners of the annual CrowdStrike Asia Pacific and Japan (APJ) Partner Awards at the CrowdStrike Partner Symposium in Bangkok. The awards recognize the exceptional work the partner ecosystem accomplished, supporting...

at 18:00
Descartes Systems Group , the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired OCR Services, Inc. ("OCR"), a leading provider of global trade compliance solutions and content. OCR specializes in...

at 18:00
The "Prepaid Cards - Global Strategic Business Report" has been added to  ResearchAndMarkets.com's offering. The global market for Prepaid Cards estimated at US$2 Trillion in the year 2023, is projected to reach a revised size of US$4.1 Trillion by...

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 18:00
On Wednesday, March 20, the Council for Agricultural Science and Technology (CAST) hosted a successful rollout event for its latest issue paper, "Applications, Benefits, and Challenges of Genome Edited Crops," at the Donald Danforth Plant Science...



News published on and distributed by: